Clinical trial of Modified Shenling Baizhu Powder in the treatment of spleen deficiency and dampness turbidity syndrome of chronic nephritis

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200006570

Enrollment

Unknown

Registered

2022-09-07

Start date

2022-09-08

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic nephritis

Interventions

Treatment group:Modified Shenling Baizhu Powder+Basic treatment

Control group:Placebo+Basic treatment

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: a) Diagnosed as chronic nephritis; b) TCM syndrome differentiation belongs to spleen and kidney qi deficiency and dampness turbidity syndrome; c) Age 18 ~ 65 years old; d) The 24-hour urinary protein content is 0.5g ~ 3g; e) eGFR>60 ml/(min·1.73m2)

Exclusion criteria

Exclusion criteria: a) Except purpura nephritis, lupus nephritis and other secondary glomerular diseases; b) Pregnant and lactating women; c) Complicated with serious mental disorders or serious cardiovascular, cerebrovascular and liver diseases.

Design outcomes

Primary

Measure	Time frame
Urine protein quantitation for 24 hours;	—

Secondary

Measure	Time frame
Albumin;Blood creatinine;Triglyceride;Glomerular filtration rate;Uric acid;Repeated or aggravated times of hematuria and proteinuria;Cholesterol;TCM symptom score;Urea nitrogen;Urine red blood cell count;	—

Countries

China

Contacts

Public ContactLi Aifeng

liaifeng016@163.com15110201932

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026